irinotecan has been researched along with taxane in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armand, JP | 1 |
| Langer, CJ | 1 |
| Blum, K; Gallipoli , M; McKeon, A; Murren, JR; Rich, R | 1 |
| Bleickardt, E; Kwong, MS; Murren, JR | 1 |
| Kelly, K | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Hejna, M; Raderer, M; Wöhrer, SS | 1 |
| Lokich, J | 1 |
| Furukawa, H; Imamura, H; Kishimoto, T; Tatsuta, M; Yamamoto, K | 1 |
| Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Kanamori, T; Kawashima, T; Murakami, H; Nakamura, Y | 1 |
| Kamura, T; Kitagawa, R; Nishio, S; Shouji, T; Sugiyama, T; Ushijima, K; Yoshizaki, A | 1 |
| Fujimoto, T; Kumagai, S; Kurachi, H; Mizunuma, H; Nakahara, K; Nishiyama, H; Omi, H; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Tase, T; Yaegashi, N; Yokoyama, Y; Yoshizaki, A | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Fukuda, H; Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Saito, I; Shibata, T | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Ilson, DH; Ku, GY | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Nakamura, K; Saitou, M; Satoh, T; Shibata, T; Takano, T; Yunokawa, M | 1 |
| Auzolle, C; Bonnetain, F; Bouché, O; Brieau, B; Coriat, R; Ducreux, M; Goujon, G; Lecomte, T; Marthey, L; Pozet, A; Prieux, C; Rougier, P; Soibinet, P; Taieb, J; Tougeron, D; Zaanan, A | 1 |
| Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
| Ahn, JH; Im, SA; Jung, KH; Kim, HJ; Kim, JH; Kim, SB; Kim, TY; Lee, KH; Lee, KS; Lee, S; Nam, BH; Park, IH; Park, KH; Park, YH; Ro, J; Sim, SH; Sohn, JH | 1 |
| Fujikawa, K; Hatachi, Y; Kato, T; Kotaka, M; Sagawa, T; Satake, H; Tsuji, A; Yasui, H | 1 |
| Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J | 1 |
8 review(s) available for irinotecan and taxane
| Article | Year |
|---|---|
New anticancer drugs in Europe.
Topics: Aminopterin; Anthraquinones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; Bridged-Ring Compounds; Bryostatins; Camptothecin; Dacarbazine; Deoxycytidine; Distamycins; Doxorubicin; Europe; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Nitrogen Mustard Compounds; Nitrosourea Compounds; Pyrazoles; Quinazolines; Taxoids; Temozolomide; Thiophenes; Vinca Alkaloids | 1997 |
The role of new agents in advanced non-small-cell lung carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2000 |
Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids | 2001 |
Camptothecin and taxane regimens for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Small Cell; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Current role of irinotecan in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Taxoids | 2002 |
Palliative chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epirubicin; Fluorouracil; Humans; Irinotecan; Palliative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Treatment Outcome | 2004 |
Chemotherapeutic options for gastroesophageal junction tumors.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Palliative Care; Stomach Neoplasms; Taxoids | 2013 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
11 trial(s) available for irinotecan and taxane
| Article | Year |
|---|---|
Same-day pegfilgrastim and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids | 2007 |
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Taxoids | 2007 |
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Ovarian Neoplasms; Research Design; Taxoids | 2012 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Young Adult | 2015 |
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Progression-Free Survival; Quality of Life; Taxoids; Treatment Outcome | 2019 |
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Platinum; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids | 2018 |
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Prognosis; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids | 2019 |
6 other study(ies) available for irinotecan and taxane
| Article | Year |
|---|---|
[Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Taxoids | 2003 |
[Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
[A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; CA-125 Antigen; Camptothecin; Carcinoma, Endometrioid; Cisplatin; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Laparotomy; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids | 2007 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Epirubicin; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovariectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2016 |